Q-omics provides the consensus-scored PI15 profile across patient tissues and cancer cell-line models. PI15 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PI15 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PI15 protein abundance shows 21,824 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where PI15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PI15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PI15 survival associations across molecular data types. PI15 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PI15 RNA expression–survival associations across cancer types. High PI15 expression shows unfavorable associations in UVM, KIRP, STAD, LGG and KIRC, but favorable associations in DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PI15 RNA expression.
This table summarizes PI15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PI15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PI15 shows lower tumor expression in UCEC, COAD and BRCA and higher tumor expression in HNSC, LUSC and LUAD. The HNSC box plot shows higher PI15 RNA expression in tumor versus normal tissue (log2 FC = +2.285, t-test p < 0.001).
This table shows molecular features associated with PI15 in patient tissues and cancer cell lines. In patient samples, PI15 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PI15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
